Eli Lilly and Co. (NYSE:LLY) on Tuesday launched Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly’s research data.
Eli Lilly estimates that this first release of AI models includes proprietary data obtained at a cost of over $1 billion.
